low - Clinical-stage biotechs are largely insulated from GDP fluctuations as development timelines are multi-year and driven by scientific/regulatory milestones rather than economic demand. However, severe recessions can impact ability to raise capital through equity markets, and healthcare budget pressures may affect future reimbursement assumptions. Rare disease oncology drugs typically maintain pricing power across cycles due to limited alternatives and life-threatening nature of indications.

Rising interest rates create significant headwinds for pre-revenue biotechs through multiple channels: (1) higher discount rates compress NPV of distant future cash flows, disproportionately impacting long-duration assets like clinical-stage pipelines, (2) risk-free rate competition makes speculative biotech equity less attractive versus bonds, (3) venture capital and biotech-focused funds face higher hurdle rates, reducing available financing. The 10-year Treasury yield directly impacts valuation multiples, with biotech indices historically showing 0.7-0.9 negative correlation to rate increases. Aura's minimal debt (11% D/E) limits direct financing cost impact, but equity financing becomes more dilutive in higher-rate environments.

growth/speculative - Attracts biotech-specialized investors, venture capital crossover funds, and retail traders seeking asymmetric risk-reward from binary clinical/regulatory catalysts. Not suitable for value or income investors given negative earnings, no dividend, and speculative nature. Typical holders include dedicated healthcare hedge funds, biotech-focused mutual funds, and high-risk-tolerance growth portfolios. The 31% one-year decline and negative cash flow profile deter momentum investors, while the Phase 3 stage (de-risked versus earlier clinical stages) attracts some crossover growth capital.